|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CNOT6L |
Gene summary for CNOT6L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CNOT6L | Gene ID | 246175 |
| Gene name | CCR4-NOT transcription complex subunit 6 like | |
| Gene Alias | CCR4b | |
| Cytomap | 4q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000288 | UniProtAcc | B4E0K8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 246175 | CNOT6L | AEH-subject4 | Human | Endometrium | AEH | 1.62e-03 | 3.67e-01 | -0.2657 |
| 246175 | CNOT6L | EEC-subject3 | Human | Endometrium | EEC | 2.21e-02 | 1.57e-02 | -0.2525 |
| 246175 | CNOT6L | EEC-subject4 | Human | Endometrium | EEC | 5.37e-04 | 3.52e-01 | -0.2571 |
| 246175 | CNOT6L | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.10e-06 | 3.65e-02 | -0.1869 |
| 246175 | CNOT6L | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.77e-04 | -1.23e-02 | -0.1875 |
| 246175 | CNOT6L | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.08e-05 | -9.48e-02 | -0.1883 |
| 246175 | CNOT6L | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.72e-09 | 1.04e-01 | -0.1934 |
| 246175 | CNOT6L | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.10e-08 | -4.02e-02 | -0.1917 |
| 246175 | CNOT6L | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.86e-13 | -9.02e-02 | -0.1916 |
| 246175 | CNOT6L | LZE4T | Human | Esophagus | ESCC | 6.60e-09 | 1.42e-01 | 0.0811 |
| 246175 | CNOT6L | LZE5T | Human | Esophagus | ESCC | 3.11e-06 | 2.96e-01 | 0.0514 |
| 246175 | CNOT6L | LZE7T | Human | Esophagus | ESCC | 2.99e-05 | 6.55e-01 | 0.0667 |
| 246175 | CNOT6L | LZE8T | Human | Esophagus | ESCC | 4.55e-10 | 1.78e-01 | 0.067 |
| 246175 | CNOT6L | LZE20T | Human | Esophagus | ESCC | 4.89e-03 | 2.33e-02 | 0.0662 |
| 246175 | CNOT6L | LZE24T | Human | Esophagus | ESCC | 1.75e-03 | 1.86e-01 | 0.0596 |
| 246175 | CNOT6L | LZE6T | Human | Esophagus | ESCC | 1.89e-06 | 1.92e-01 | 0.0845 |
| 246175 | CNOT6L | P1T-E | Human | Esophagus | ESCC | 3.22e-04 | 2.12e-01 | 0.0875 |
| 246175 | CNOT6L | P2T-E | Human | Esophagus | ESCC | 4.41e-25 | 2.79e-01 | 0.1177 |
| 246175 | CNOT6L | P4T-E | Human | Esophagus | ESCC | 2.62e-15 | 2.33e-01 | 0.1323 |
| 246175 | CNOT6L | P5T-E | Human | Esophagus | ESCC | 7.61e-11 | 1.79e-02 | 0.1327 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000640217 | Prostate | Tumor | mRNA catabolic process | 87/3246 | 232/18723 | 1.56e-13 | 1.73e-11 | 87 |
| GO:003133119 | Prostate | Tumor | positive regulation of cellular catabolic process | 134/3246 | 427/18723 | 5.54e-13 | 5.84e-11 | 134 |
| GO:000640117 | Prostate | Tumor | RNA catabolic process | 94/3246 | 278/18723 | 1.77e-11 | 1.25e-09 | 94 |
| GO:000095615 | Prostate | Tumor | nuclear-transcribed mRNA catabolic process | 46/3246 | 112/18723 | 2.80e-09 | 1.17e-07 | 46 |
| GO:006101315 | Prostate | Tumor | regulation of mRNA catabolic process | 57/3246 | 166/18723 | 8.79e-08 | 2.39e-06 | 57 |
| GO:003465516 | Prostate | Tumor | nucleobase-containing compound catabolic process | 112/3246 | 407/18723 | 1.61e-07 | 4.02e-06 | 112 |
| GO:004348815 | Prostate | Tumor | regulation of mRNA stability | 54/3246 | 158/18723 | 2.26e-07 | 5.42e-06 | 54 |
| GO:003424912 | Prostate | Tumor | negative regulation of cellular amide metabolic process | 80/3246 | 273/18723 | 6.33e-07 | 1.32e-05 | 80 |
| GO:004670014 | Prostate | Tumor | heterocycle catabolic process | 117/3246 | 445/18723 | 1.11e-06 | 2.10e-05 | 117 |
| GO:004427015 | Prostate | Tumor | cellular nitrogen compound catabolic process | 118/3246 | 451/18723 | 1.30e-06 | 2.39e-05 | 118 |
| GO:004348715 | Prostate | Tumor | regulation of RNA stability | 54/3246 | 170/18723 | 3.00e-06 | 4.95e-05 | 54 |
| GO:190331314 | Prostate | Tumor | positive regulation of mRNA metabolic process | 41/3246 | 118/18723 | 3.86e-06 | 6.18e-05 | 41 |
| GO:001714812 | Prostate | Tumor | negative regulation of translation | 71/3246 | 245/18723 | 4.08e-06 | 6.51e-05 | 71 |
| GO:190136114 | Prostate | Tumor | organic cyclic compound catabolic process | 124/3246 | 495/18723 | 7.37e-06 | 1.10e-04 | 124 |
| GO:190211711 | Prostate | Tumor | positive regulation of organelle assembly | 27/3246 | 67/18723 | 7.76e-06 | 1.16e-04 | 27 |
| GO:001943914 | Prostate | Tumor | aromatic compound catabolic process | 118/3246 | 467/18723 | 7.92e-06 | 1.17e-04 | 118 |
| GO:006101414 | Prostate | Tumor | positive regulation of mRNA catabolic process | 30/3246 | 87/18723 | 8.61e-05 | 8.53e-04 | 30 |
| GO:006115714 | Prostate | Tumor | mRNA destabilization | 29/3246 | 84/18723 | 1.09e-04 | 1.04e-03 | 29 |
| GO:000028914 | Prostate | Tumor | nuclear-transcribed mRNA poly(A) tail shortening | 14/3246 | 29/18723 | 1.22e-04 | 1.14e-03 | 14 |
| GO:005077914 | Prostate | Tumor | RNA destabilization | 29/3246 | 88/18723 | 2.74e-04 | 2.25e-03 | 29 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030187 | Endometrium | EEC | RNA degradation | 20/1237 | 79/8465 | 8.36e-03 | 3.88e-02 | 2.89e-02 | 20 |
| hsa0301812 | Endometrium | EEC | RNA degradation | 20/1237 | 79/8465 | 8.36e-03 | 3.88e-02 | 2.89e-02 | 20 |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa030188 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
| hsa0301813 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
| hsa0301822 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
| hsa0301832 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CNOT6L | SNV | Missense_Mutation | c.241N>G | p.Leu81Val | p.L81V | Q96LI5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| CNOT6L | SNV | Missense_Mutation | c.388C>G | p.Leu130Val | p.L130V | Q96LI5 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CNOT6L | SNV | Missense_Mutation | rs752836467 | c.82G>T | p.Val28Leu | p.V28L | Q96LI5 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| CNOT6L | SNV | Missense_Mutation | rs752836467 | c.82N>T | p.Val28Leu | p.V28L | Q96LI5 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CNOT6L | SNV | Missense_Mutation | rs752836467 | c.82G>T | p.Val28Leu | p.V28L | Q96LI5 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CNOT6L | insertion | Frame_Shift_Ins | novel | c.1268_1269insGAAATCTAAAC | p.Ser424LysfsTer9 | p.S424Kfs*9 | Q96LI5 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| CNOT6L | deletion | Frame_Shift_Del | novel | c.876delN | p.Phe292LeufsTer26 | p.F292Lfs*26 | Q96LI5 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CNOT6L | SNV | Missense_Mutation | novel | c.700G>T | p.Asp234Tyr | p.D234Y | Q96LI5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CNOT6L | SNV | Missense_Mutation | novel | c.289G>A | p.Glu97Lys | p.E97K | Q96LI5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CNOT6L | SNV | Missense_Mutation | novel | c.79G>A | p.Glu27Lys | p.E27K | Q96LI5 | protein_coding | tolerated(0.11) | possibly_damaging(0.786) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |